Innovent's IBI363 Plus Bevacizumab Cuts Progression or Death Risk 60% in Phase 1b Lung Cancer Trial

• Innovent Biologics announced Oct. 25, 2026, that Phase 1b results for IBI363/TAK-928, jointly developed with Takeda, were presented at ESMO.
• In immunotherapy-resistant lung adenocarcinoma, IBI363/TAK-928 combined with bevacizumab significantly reduced disease progression or death risk versus docetaxel; overall survival remained immature.
• First-line chemotherapy combinations showed antitumor activity in lung cancer with low or negative PD-L1 expression and HER2-negative gastric or gastroesophageal junction cancer.
• Safety remained manageable across the studies, with no new safety signals identified.
• A global Phase 3 monotherapy trial remains underway; first-line randomized testing is ongoing in lung cancer and planned for gastric cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610252000PR_NEWS_USPR_____CN80403) on October 26, 2026, and is solely responsible for the information contained therein.